Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Payables: 2021-2024

Historic Payables for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $4,913.

  • ProQR Therapeutics N.V's Payables rose 19.67% to $5,968 in Q3 2025 from the same period last year, while for Sep 2025 it was $23,017, marking a year-over-year decrease of 98.63%. This contributed to the annual value of $4,913 for FY2024, which is 22.13% down from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Payables stood at $4,913 for FY2024, which was down 22.13% from $6,310 recorded in FY2023.
  • ProQR Therapeutics N.V's Payables' 5-year high stood at $5.9 million during FY2021, with a 5-year trough of $4,913 in FY2024.
  • In the last 3 years, ProQR Therapeutics N.V's Payables had a median value of $6,310 in 2023 and averaged $1.6 million.
  • Data for ProQR Therapeutics N.V's Payables shows a maximum YoY slumped of 99.87% (in 2023) over the last 5 years.
  • Over the past 4 years, ProQR Therapeutics N.V's Payables (Yearly) stood at $5.9 million in 2021, then dropped by 18.98% to $4.8 million in 2022, then crashed by 99.87% to $6,310 in 2023, then fell by 22.13% to $4,913 in 2024.